Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense.
The BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, and a novel innate defense regulator (IDR) technology, dusquetide (SGX942), for the treatment of oral mucositis in head-and-neck cancer.